BACKGROUND: Studies conducted in Asian populations have suggested that high consumption of soy-based foods that are rich in isoflavone phytoestrogens is associated with a reduced risk of breast cancer. However, the potential associations of other dietary phytoestrogens--i.e., the lignans or their bioactive metabolites, the enterolignans--with the risk of breast cancer are unclear. METHODS: We prospectively examined associations between the risk of postmenopausal invasive breast cancer and dietary intakes of four plant lignans (pinoresinol, lariciresinol, secoisolariciresinol, and matairesinol) and estimated exposure to two enterolignans (enterodiol and enterolactone), as measured with a self-administered diet history questionnaire, among 58,049 postmenopausal French women who were not taking soy isoflavone supplements. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models. Analyses were further stratified by the combined estrogen and progesterone receptor (ER/PR) status of the tumors. Statistical tests were two-sided. RESULTS: During 383,425 person-years of follow-up (median follow-up, 7.7 years), 1469 cases of breast cancer were diagnosed. Compared with women in the lowest intake quartiles, those in the highest quartile of total lignan intake (>1395 microg/day) had a reduced risk of breast cancer (RR = 0.83, 95% CI = 0.71 to 0.95, P(trend) = .02, 376 versus 411 cases per 100,000 person-years), as did those in the highest quartile of lariciresinol intake (RR = 0.82, 95% CI = 0.71 to 0.95, P(trend) = .01). The inverse associations between phytoestrogen intakes and postmenopausal breast cancer risk were limited to ER- and PR-positive disease (e.g., RR for highest versus lowest quartiles of total plant lignan intake = 0.72, 95% CI = 0.58 to 0.88, P(trend) = .01, 174 versus 214 cases per 100,000 person-years, and RR for highest versus lowest quartiles of total enterolignan level = 0.77, 95% CI = 0.62 to 0.95, P(trend) = .01, 164 versus 204 cases per 100,000 person-years). CONCLUSIONS: High dietary intakes of plant lignans and high exposure to enterolignans were associated with reduced risks of ER- and PR-positive postmenopausal breast cancer in a Western population that does not consume a diet rich in soy.
BACKGROUND: Studies conducted in Asian populations have suggested that high consumption of soy-based foods that are rich in isoflavone phytoestrogens is associated with a reduced risk of breast cancer. However, the potential associations of other dietary phytoestrogens--i.e., the lignans or their bioactive metabolites, the enterolignans--with the risk of breast cancer are unclear. METHODS: We prospectively examined associations between the risk of postmenopausal invasive breast cancer and dietary intakes of four plant lignans (pinoresinol, lariciresinol, secoisolariciresinol, and matairesinol) and estimated exposure to two enterolignans (enterodiol and enterolactone), as measured with a self-administered diet history questionnaire, among 58,049 postmenopausal French women who were not taking soy isoflavone supplements. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards regression models. Analyses were further stratified by the combined estrogen and progesterone receptor (ER/PR) status of the tumors. Statistical tests were two-sided. RESULTS: During 383,425 person-years of follow-up (median follow-up, 7.7 years), 1469 cases of breast cancer were diagnosed. Compared with women in the lowest intake quartiles, those in the highest quartile of total lignan intake (>1395 microg/day) had a reduced risk of breast cancer (RR = 0.83, 95% CI = 0.71 to 0.95, P(trend) = .02, 376 versus 411 cases per 100,000 person-years), as did those in the highest quartile of lariciresinol intake (RR = 0.82, 95% CI = 0.71 to 0.95, P(trend) = .01). The inverse associations between phytoestrogen intakes and postmenopausal breast cancer risk were limited to ER- and PR-positive disease (e.g., RR for highest versus lowest quartiles of total plant lignan intake = 0.72, 95% CI = 0.58 to 0.88, P(trend) = .01, 174 versus 214 cases per 100,000 person-years, and RR for highest versus lowest quartiles of total enterolignan level = 0.77, 95% CI = 0.62 to 0.95, P(trend) = .01, 164 versus 204 cases per 100,000 person-years). CONCLUSIONS: High dietary intakes of plant lignans and high exposure to enterolignans were associated with reduced risks of ER- and PR-positive postmenopausal breast cancer in a Western population that does not consume a diet rich in soy.
Authors: Isabel dos Santos Silva; Punam Mangtani; Valerie McCormack; Dee Bhakta; Anthony J McMichael; Leena Sevak Journal: Cancer Causes Control Date: 2004-10 Impact factor: 2.506
Authors: L Remontet; J Estève; A-M Bouvier; P Grosclaude; G Launoy; F Menegoz; C Exbrayat; B Tretare; P-M Carli; A-V Guizard; X Troussard; P Bercelli; M Colonna; J-M Halna; G Hedelin; J Macé-Lesec'h; J Peng; A Buemi; M Velten; E Jougla; P Arveux; L Le Bodic; E Michel; M Sauvage; C Schvartz; J Faivre Journal: Rev Epidemiol Sante Publique Date: 2003-02 Impact factor: 1.019
Authors: Pamela L Horn-Ross; K J Hoggatt; Dee W West; Melissa R Krone; Susan L Stewart; Hoda Anton; Culver Leslie Bernstei; Dennis Deapen; David Peel; Richard Pinder; Peggy Reynolds; Ronald K Ross; William Wright; Al Ziogas Journal: Cancer Causes Control Date: 2002-06 Impact factor: 2.506
Authors: Annamari Kilkkinen; Jarmo Virtamo; Erkki Vartiainen; Risto Sankila; Mikko J Virtanen; Herman Adlercreutz; Pirjo Pietinen Journal: Int J Cancer Date: 2004-01-10 Impact factor: 7.396
Authors: P Ferrari; N Slimani; A Ciampi; A Trichopoulou; A Naska; C Lauria; F Veglia; H B Bueno-de-Mesquita; M C Ocké; M Brustad; T Braaten; M José Tormo; P Amiano; I Mattisson; G Johansson; A Welch; G Davey; K Overvad; A Tjønneland; F Clavel-Chapelon; A Thiebaut; J Linseisen; H Boeing; B Hemon; E Riboli Journal: Public Health Nutr Date: 2002-12 Impact factor: 4.022
Authors: G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson Journal: Endocrinology Date: 1998-10 Impact factor: 4.736
Authors: A Zeleniuch-Jacquotte; H Adlercreutz; R E Shore; K L Koenig; I Kato; A A Arslan; P Toniolo Journal: Br J Cancer Date: 2004-07-05 Impact factor: 7.640
Authors: Carol J Fabian; Bruce F Kimler; Carola M Zalles; Jennifer R Klemp; Brian K Petroff; Qamar J Khan; Priyanka Sharma; Kenneth D R Setchell; Xueheng Zhao; Teresa A Phillips; Trina Metheny; Jennifer R Hughes; Hung-Wen Yeh; Karen A Johnson Journal: Cancer Prev Res (Phila) Date: 2010-08-19
Authors: Giorgio Biasiotto; Marialetizia Penza; Isabella Zanella; Moris Cadei; Luigi Caimi; Cristina Rossini; Annika I Smeds; Diego Di Lorenzo Journal: Eur J Nutr Date: 2014-02-25 Impact factor: 5.614
Authors: Carol J Fabian; Seema A Khan; Judy E Garber; William C Dooley; Lisa D Yee; Jennifer R Klemp; Jennifer L Nydegger; Kandy R Powers; Amy L Kreutzjans; Carola M Zalles; Trina Metheny; Teresa A Phillips; Jinxiang Hu; Devin C Koestler; Prabhakar Chalise; Nanda Kumar Yellapu; Cheryl Jernigan; Brian K Petroff; Stephen D Hursting; Bruce F Kimler Journal: Cancer Prev Res (Phila) Date: 2020-04-20
Authors: Huiru Chang; Song Yao; David Tritchler; Meredith A Hullar; Johanna W Lampe; Lilian U Thompson; Susan E McCann Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-02 Impact factor: 4.254
Authors: Marc T Goodman; Yurii B Shvetsov; Lynne R Wilkens; Adrian A Franke; Loic Le Marchand; Kerry K Kakazu; Abraham M Y Nomura; Brian E Henderson; Laurence N Kolonel Journal: Cancer Prev Res (Phila) Date: 2009-09-29